Patent application number | Description | Published |
20100298260 | NON-ANTICOAGULANT POLYSACCHARIDE COMPOSITIONS - Preparations of polysaccharides lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided. | 11-25-2010 |
20100316640 | POLYSACCHARIDE COMPOSITIONS AND METHODS OF USE FOR THE TREATMENT AND PREVENTION OF DISORDERS ASSOCIATED WITH PROGENITOR CELL MOBILIZATION - Polysaccharide preparations lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided. | 12-16-2010 |
20100324276 | POLYSACCHARIDE COMPOSITIONS AND METHODS OF USE FOR THE TREATMENT AND PREVENTION OF DISORDERS ASSOCIATED WITH PROGENITOR CELL MOBILIZATION - Polysaccharide preparations lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided. | 12-23-2010 |
20110053203 | COPOLYMER ASSAY - The present invention provides methods and compositions for evaluating one or more properties of an amino acid copolymer. | 03-03-2011 |
20110201801 | SACCHARIDE STRUCTURES AND METHODS OF MAKING AND USING SUCH STRUCTURES - Described are oligosaccharides having a protecting group at two, a plurality, a majority of, or each position in the oligosaccharide which is amenable to derivatization. Collections, libraries and methods of making and using such oligosaccharides are also described. | 08-18-2011 |
20120183976 | METHODS OF ASSESSING ACTIVITY OF A POLYSACCHARIDE COMPOSITION - Methods of assessing polysaccharide preparations lacking substantial anticoagulant activity are provided herein. | 07-19-2012 |
20120276109 | TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE IMMUNE RESPONSES TO THERAPEUTIC PROTEINS - Disclosed are synthetic nanocarrier compositions, and related methods, comprising therapeutic protein APC presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to therapeutic proteins. | 11-01-2012 |
20120276134 | TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ANTIGEN-SPECIFIC DELETION OF T EFFECTOR CELLS - Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering immunosuppressants and MHC Class I-restricted and/or MHC Class II-restricted epitopes that can generate tolerogenic immune responses (e.g., antigen-specific T effector cell deletion). | 11-01-2012 |
20120276155 | TOLEROGENIC SYNTHETIC NANOCARRIERS FOR GENERATING CD8+ REGULATORY T CELLS - Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells. | 11-01-2012 |
20120276156 | TOLEROGENIC SYNTHETIC NANOCARRIER COMPOSITIONS WITH TRANSPLANTABLE GRAFT ANTIGENS AND METHODS OF USE - Disclosed are synthetic nanocarrier compositions, and related methods, comprising APC presentable transplant antigens and immunosuppressants that provide tolerogenic immune responses (e.g., a reduction in CD8+ T cell proliferation and/or activity) specific to the APC presentable transplant antigens. | 11-01-2012 |
20120276157 | TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE ANTIBODY RESPONSES - Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class II-restricted epitopes and immunosuppressants that provide tolerogenic immune responses, such as a reduction in CD4+ T cell help specific to an antigen. | 11-01-2012 |
20120276158 | TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE CYTOTOXIC T LYMPHOCYTE RESPONSES - Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class I-restricted and/or MHC Class II-restricted epitopes associated with undesired CD8+ T cell responses and immunosuppressants that provide tolerogenic immune responses against antigens that comprise the epitopes. | 11-01-2012 |
20120294888 | TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ALLERGY THERAPY - Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen. | 11-22-2012 |
20120301510 | TOLEROGENIC SYNTHETIC NANOCARRIERS COUPLED TO CD1D-RESTRICTED ANTIGENS AND METHODS OF USE - Disclosed are synthetic nanocarrier compositions, and related methods, comprising CD1d-restricted antigens and immunosuppressants that provide tolerogenic immune responses. | 11-29-2012 |
20130058894 | THERAPEUTIC PROTEIN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS AND METHODS OF USE - Disclosed are therapeutic protein-specific induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods. | 03-07-2013 |
20130058901 | TRANSPLANTABLE GRAFT-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS AND METHODS OF USE - Disclosed are transplantable graft-specific induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods. | 03-07-2013 |
20130058902 | DENDRITIC CELL SUBSETS FOR GENERATING INDUCED TOLEROGENIC DENDRITIC CELLS AND RELATED COMPOSITIONS AND METHODS - Disclosed are induced tolerogenic dendritic cells (itDCs) produced from dendritic cell subsets that possess a desired physiological characteristic, as well as related compositions and methods. | 03-07-2013 |
20130058963 | INDUCED TOLEROGENIC DENDRITIC CELLS FOR GENERATING CD8+ REGULATORY T CELLS - Disclosed are antigen-specific induced tolerogenic dendritic cells (itDCs) that generate CD8+ regulatory T cells, as well as related compositions and methods. | 03-07-2013 |
20130058970 | INDUCED TOLEROGENIC DENDRITIC CELLS TO REDUCE SYSTEMIC INFLAMMATORY CYTOKINES - Disclosed are induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods, for reducing systemic inflammatory cytokines. | 03-07-2013 |
20130058974 | ANTIGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS TO REDUCE CYTOTOXIC T LYMPHOCYTE RESPONSES - Disclosed are antigen-specific induced tolerogenic dendritic cells (itDCs) for reducing CD8+ T cell immune responses, as well as related compositions and methods. | 03-07-2013 |
20130058975 | ANTIGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS TO REDUCE ANTIBODY RESPONSES - Disclosed are antigen-specific induced tolerogenic dendritic cells (itDCs) for reducing undesired humoral immune responses, as well as related compositions and methods. | 03-07-2013 |
20130058976 | ALLERGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS FOR ALLERGY THERAPY - Disclosed are allergen-specific induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods. | 03-07-2013 |
20130058977 | COMPOSITIONS AND METHODS RELATED TO INDUCED TOLEROGENIC DENDRITIC CELLS EXTERNALLY LOADED WITH MHC CLASS I-RESTRICTED EPITOPES - Disclosed are induced tolerogenic dendritic cells (itDCs) produced by combining itDCs with externally loadable MHC Class I-restricted epitopes, as well as related compositions and methods. | 03-07-2013 |
20130059009 | COMPOSITIONS AND METHODS FOR PRODUCING ANTIGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS WITH SYNTHETIC NANOCARRIERS - Disclosed are antigen-specific induced tolerogenic dendritic cells (itDCs) that are produced from combining itDCs with antigen in particulate form, as well as related compositions and methods. | 03-07-2013 |
20130156698 | TISSUE TARGETING - Methods and compositions related to targeting agents to tumor tissue are described. | 06-20-2013 |
20140024602 | POLYSACCHARIDE COMPOSITIONS AND METHODS OF USE FOR THE TREATMENT AND PREVENTION OF DISORDERS ASSOCIATED WITH PROGENITOR CELL MOBILIZATION - Polysaccharide preparations lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided. | 01-23-2014 |
20140031315 | POLYSACCHARIDE COMPOSITIONS AND METHODS OF USE FOR THE TREATMENT AND PREVENTION OF DISORDERS ASSOCIATED WITH PROGENITOR CELL MOBILIZATION - Polysaccharide preparations lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided. | 01-30-2014 |
20140328854 | TOLEROGENIC SYNTHETIC NANOCARRIERS AND THERAPEUTIC MACROMOLECULES FOR REDUCED OR ENHANCED PHARMACODYNAMIC EFFECTS - Disclosed are compositions and methods that provide pharmacodynamic effects specific to therapeutic macromolecules. The effects may result from reduced doses of therapeutic macromolecules in combination with immunosuppressant doses. The effects may also be enhanced with such compositions. | 11-06-2014 |
20140328923 | DOSING COMBINATIONS FOR REDUCING UNDESIRED HUMORAL IMMUNE RESPONSES - Disclosed are dosings of therapeutic macromolecules and immunosuppressants, in some embodiments attached to synthetic nanocarriers, in combination with dosings of therapeutic macromolecules without synthetic nanocarriers, and related methods that provide reduced humoral immune responses. | 11-06-2014 |
20140328924 | DELIVERY OF IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE-LIFE AND ANTIGEN FOR THE INDUCTION OF IMMUNE TOLERANCE - This invention relates to methods that provide immunosuppressants and therapeutic macromolecules that are administered within a pharmacodynamically effective window of the immunosuppressants to induce immune tolerance to the therapeutic macromolecules. The methods allow shifting the immune response in favor of tolerogenic immune response development specific to the therapeutic macromolecule. | 11-06-2014 |
20140335186 | METHODS AND COMPOSITIONS FOR ENHANCING CD4+ REGULATORY T CELLS - Disclosed are methods and related compositions for administering immunosuppressants and therapeutic macromolecules for enhancing CD4+ regulatory T cells. | 11-13-2014 |
20140356361 | REPEATED ADMINISTRATION OF NON-IMMUNOSUPPRESSIVE ANTIGEN SPECIFIC IMMUNOTHERAPEUTICS - This invention relates to repeated administration of antigen-specific immunotherapeutics using protocols, or elements thereof, that do not induce immunosuppression. In some embodiments, the protocol has been previously shown not to induce immunosuppression in a subject. | 12-04-2014 |